New Preliminary Studies with Hydroxychloroquine:

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial – International Journal of Antimicrobial Agents (free PDF)

This was an open-label study with only 42 patients without patient-relevant endpoints. The 6 patients that received Hydroxychloroquine + Azithromycin achieved more efficient virus elimination than control patients.

New in Vitro Study: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro – Cell Discovery (free)

Related Articles: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – Clinical Infectious Diseases (free PDF) AND New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? – International Journal of Antimicrobial Agents (free) AND A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 – Journal of Critical Care (free) AND Of chloroquine and COVID-19 – Antiviral Research (free)